Market Closed -
Nasdaq
04:00:00 2024-06-13 pm EDT
|
5-day change
|
1st Jan Change
|
24.7
USD
|
-0.52%
|
|
-10.54%
|
-29.23%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,099
|
2,219
|
-
|
-
|
Enterprise Value (EV)
1 |
4,583
|
3,793
|
3,660
|
3,511
|
P/E ratio
|
-873
x
|
-23.6
x
|
40.8
x
|
19
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1
x
|
0.79
x
|
0.76
x
|
0.72
x
|
EV / Revenue
|
1.47
x
|
1.35
x
|
1.25
x
|
1.14
x
|
EV / EBITDA
|
17.1
x
|
16
x
|
10.6
x
|
9.01
x
|
EV / FCF
|
36.1
x
|
49.3
x
|
22
x
|
15.9
x
|
FCF Yield
|
2.77%
|
2.03%
|
4.55%
|
6.3%
|
Price to Book
|
1.78
x
|
1.27
x
|
1.15
x
|
1.05
x
|
Nbr of stocks (in thousands)
|
88,800
|
89,374
|
-
|
-
|
Reference price
2 |
34.90
|
24.70
|
24.70
|
24.70
|
Announcement Date
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,109
|
2,801
|
2,927
|
3,092
|
EBITDA
1 |
-
|
267.3
|
236.8
|
346.8
|
389.5
|
EBIT
1 |
-
|
170.9
|
185.6
|
313.9
|
350.3
|
Operating Margin
|
-
|
5.5%
|
6.62%
|
10.72%
|
11.33%
|
Earnings before Tax (EBT)
1 |
237
|
1.1
|
-174
|
-42.53
|
45.08
|
Net income
1 |
192.9
|
-3.4
|
-122.6
|
42.22
|
76.7
|
Net margin
|
-
|
-0.11%
|
-4.38%
|
1.44%
|
2.48%
|
EPS
2 |
-
|
-0.0400
|
-1.045
|
0.6050
|
1.297
|
Free Cash Flow
1 |
-
|
127.1
|
76.93
|
166.5
|
221.2
|
FCF margin
|
-
|
4.09%
|
2.75%
|
5.69%
|
7.15%
|
FCF Conversion (EBITDA)
|
-
|
47.55%
|
32.49%
|
48%
|
56.79%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
394.24%
|
288.4%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
793
|
776.4
|
775.4
|
662.1
|
688.4
|
715.3
|
732.4
|
703.8
|
723.4
|
EBITDA
1 |
72.5
|
70.5
|
67.2
|
29.5
|
51.4
|
70.16
|
86.72
|
62.71
|
81.54
|
EBIT
1 |
63
|
45.9
|
43.3
|
7.6
|
37.83
|
55.23
|
78.66
|
54.13
|
81.41
|
Operating Margin
|
7.94%
|
5.91%
|
5.58%
|
1.15%
|
5.5%
|
7.72%
|
10.74%
|
7.69%
|
11.25%
|
Earnings before Tax (EBT)
|
-
|
-
|
-41
|
-77.5
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
28.3
|
-13.1
|
-36
|
-102.8
|
-34.92
|
-12.33
|
-4.827
|
-11.85
|
4.4
|
Net margin
|
3.57%
|
-1.69%
|
-4.64%
|
-15.53%
|
-5.07%
|
-1.72%
|
-0.66%
|
-1.68%
|
0.61%
|
EPS
2 |
0.3200
|
-0.1500
|
-0.4100
|
-1.150
|
-0.2533
|
0.0100
|
0.1200
|
-0.0300
|
0.0950
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/14/23
|
11/13/23
|
3/11/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
1,483
|
1,574
|
1,441
|
1,292
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
5.55
x
|
6.647
x
|
4.155
x
|
3.318
x
|
Free Cash Flow
1 |
-
|
127
|
76.9
|
166
|
221
|
ROE (net income / shareholders' equity)
|
-
|
4.9%
|
3.86%
|
7.71%
|
7.99%
|
ROA (Net income/ Total Assets)
|
-
|
2.88%
|
0.9%
|
2.11%
|
3.52%
|
Assets
1 |
-
|
-118
|
-13,673
|
2,001
|
2,178
|
Book Value Per Share
2 |
-
|
19.60
|
19.50
|
21.40
|
23.50
|
Cash Flow per Share
2 |
-
|
1.970
|
0.2200
|
2.430
|
2.230
|
Capex
1 |
-
|
40.3
|
51.9
|
46.2
|
56.9
|
Capex / Sales
|
-
|
1.3%
|
1.85%
|
1.58%
|
1.84%
|
Announcement Date
|
5/15/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
24.83
USD Average target price
31.8
USD Spread / Average Target +28.07% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.23% | 2.22B | | +46.03% | 56.61B | | -7.53% | 39.62B | | +36.02% | 39.25B | | -9.38% | 28.28B | | +12.31% | 26.44B | | -16.38% | 20.12B | | +30.79% | 12.51B | | +28.57% | 12.48B | | -0.36% | 12.2B |
Other Biotechnology & Medical Research
|